Digital pathology and artificial intelligence are transforming the drug development landscape, accelerating the path to ...
The Manila Times on MSNOpinion
Who will teach students to understand society?
“The highest education is that which does not merely give us information but makes our life in harmony with all existence.” — ...
Large Language Models (LLMs) such as GPT-4, Gemini-Pro, Llama 2, and medical-domain-tuned variants like Med-PaLM 2 have ...
In collaboration with the Gorlin Syndrome Alliance, Medicus is pursuing an Expanded Access IND program to provide Gorlin Syndrome patients with multiple or inoperable BCCs access to SkinJect™, the ...
David J. Adams serves as Indiana’s Secretary of Commerce and a member of Governor Mike Braun’s cabinet. Since his appointment in 2025, Adams has been instrumental in the transforming the state’s ...
The U.S. life sciences industry entered 2026 with surprising momentum, following threats of tariffs and disrupted trade, NIH funding cuts, and a sluggish IPO market. Accounting for more than ...
April 16 - OpenAI on Thursday introduced an artificial intelligence model touting increased biology knowledge and scientific research capabilities, as the startup deepens its push into the life ...
El Salvador has published a new law that will allow authorities to penalise minors as young as 12 with life imprisonment for severe crimes, including homicide, terrorism or rape. On Tuesday, the ...
One of the world’s leading investment firms has broken its own record with the closing of its $6.3 billion Blackstone Life Sciences VI (BLXS VI) fund, which is 40% larger than its predecessor.
Blackstone Inc. closed its latest life-sciences fund with $6.3 billion of commitments, the firm’s biggest haul for backing clinical trials of medicines and technologies. The new vehicle, Blackstone ...
March 26 (Reuters) - Wave Life Sciences (WVE.O), opens new tab shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...
Wave Life Sciences (WVE) fell ~57% in the premarket on Thursday as Wall Street reacted to interim data from an early-stage trial for WVE-007, its RNA-based obesity medicine. Citing six-month follow-up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results